Evaluating the effect of metformin on sarcopenia: A Mendelian randomization study

Area of Science:

• Gerontology
• Metabolic Disorders
• Pharmacogenetics

Background:

• Sarcopenia is common in older adults with type 2 diabetes.
• Metformin, a primary diabetes drug, has uncertain effects on sarcopenia.
• Investigating metformin's causal impact on muscle health is crucial.

Purpose of the Study:

• To evaluate the causal effect of metformin on sarcopenia indicators.
• To utilize Mendelian randomization for assessing genetic associations with metformin use and muscle parameters.

Main Methods:

• Mendelian randomization analysis using genome-wide association study data.
• Employed inverse variance weighted (IVW), MR-Egger, and weighted median methods.
• Conducted heterogeneity, pleiotropy, and sensitivity analyses for robust findings.

Main Results:

• Metformin use showed a significant causal association with reduced right and left hand grip strength (P<0.05).
• No significant causal relationship was observed between metformin use and walking pace or appendicular lean mass.
• Sensitivity analyses confirmed the robustness of the findings regarding hand grip strength.

Conclusions:

• Long-term metformin use may be causally linked to decreased hand grip strength in individuals with type 2 diabetes.
• Caution is advised regarding metformin's potential impact on muscle strength in this population.
• Further studies should explore mechanisms and clinical implications of metformin on sarcopenia.